GenMark Diagnostics, Inc (NASDAQ:GNMK) Director Michael Kagnoff bought 10,000 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was purchased at an average price of $4.22 per share, with a total value of $42,200.00. Following the transaction, the director now owns 74,413 shares in the company, valued at approximately $314,022.86. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
GenMark Diagnostics, Inc (NASDAQ GNMK) traded down $0.16 during trading hours on Wednesday, reaching $5.32. The company had a trading volume of 163,323 shares, compared to its average volume of 389,287. GenMark Diagnostics, Inc has a twelve month low of $3.63 and a twelve month high of $13.67. The firm has a market cap of $291.51, a price-to-earnings ratio of -4.36 and a beta of 0.99. The company has a quick ratio of 3.04, a current ratio of 3.44 and a debt-to-equity ratio of 0.29.
GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.26). GenMark Diagnostics had a negative return on equity of 91.14% and a negative net margin of 117.77%. The business had revenue of $16.02 million during the quarter, compared to analyst estimates of $15.82 million. sell-side analysts forecast that GenMark Diagnostics, Inc will post -0.78 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in GenMark Diagnostics by 7.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,396,940 shares of the medical equipment provider’s stock valued at $41,288,000 after purchasing an additional 299,173 shares during the period. Jennison Associates LLC boosted its position in GenMark Diagnostics by 0.7% during the 3rd quarter. Jennison Associates LLC now owns 3,567,001 shares of the medical equipment provider’s stock valued at $34,350,000 after purchasing an additional 25,254 shares during the period. Vanguard Group Inc. boosted its position in GenMark Diagnostics by 10.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,169,476 shares of the medical equipment provider’s stock valued at $25,664,000 after purchasing an additional 212,795 shares during the period. Alyeska Investment Group L.P. boosted its position in GenMark Diagnostics by 52.7% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,013,881 shares of the medical equipment provider’s stock valued at $9,764,000 after purchasing an additional 349,819 shares during the period. Finally, State Street Corp boosted its position in GenMark Diagnostics by 9.4% during the 2nd quarter. State Street Corp now owns 888,727 shares of the medical equipment provider’s stock valued at $10,515,000 after purchasing an additional 76,010 shares during the period.
Several research analysts have recently commented on the company. Canaccord Genuity decreased their target price on GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of GenMark Diagnostics in a research report on Friday, January 19th. BidaskClub upgraded GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 7th. Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BTIG Research set a $11.00 target price on GenMark Diagnostics and gave the stock a “buy” rating in a research report on Monday, November 20th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.60.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.